Conferences
ASCO GU 2024: Discussant: Adjuvant Treatment for RCC – Strategies on How to Optimize Patient Selection for The New Standard of Care
January 27, 2024
ASCO GU 2024: Overall Survival Results from the Phase 3 KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell RCC
January 27, 2024
ASCO GU 2024: Sequential Endoluminal Gemcitabine and Docetaxel vs BCG for the Treatment of High-grade UTUC
January 27, 2024
ASCO GU 2024: Sequencing of Erdafitinib and Enfortumab Vedotin in Patients with FGFR2/3 Altered Advanced Urothelial Cancer: Analysis of UNITE Database
January 27, 2024
ASCO GU 2024: Interim Analysis of a Phase I/Ib Study of Enfortumab Vedotin plus Cabozantinib in Patients with Metastatic Urothelial Carcinoma
January 27, 2024